J&J buys a developer of therapies for serious eye diseases

Johnson & Johnson (J&J) has entered into a denitive agreement to acquire Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments of up to $1.125 billion.

Already an Eyewear Intelligence subscriber? Sign in here.

barrier_image_OIC

Subscribe today

Buying a membership today will give you:

  • Unlimited access to ewintelligence.com - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation
  • Organisation-wide access across offices, people and devices

To continue reading this article register now.